Key result
Mitral Myval implantation shows 100% technical success in valve-in-valve and valve-in-ring procedures with zero 4-year deterioration.
Why the study?
Transcatheter implantation of balloon-expandable valves in non-aortic positions is a growing off-label strategy for valve-in-valve and valve-in-ring procedures in high-risk patients, warranting evaluation of 4-year clinical outcomes and echocardiographic performance of the Myval THV.
Does off-label transcatheter implantation of the Myval THV provide adequate 4-year clinical outcomes and echocardiographic performance in high-risk patients undergoing mitral, tricuspid, and pulmonary valve-in-valve or valve-in-ring procedures?
Observational (n=33)
Does off-label transcatheter implantation of the Myval THV provide adequate 4-year clinical outcomes and echocardiographic performance in high-risk patients undergoing mitral, tricuspid, and pulmonary valve-in-valve or valve-in-ring procedures?
Off-label transcatheter implantation of the balloon-expandable Myval valve in mitral, tricuspid, and pulmonary positions demonstrated high technical success, acceptable 4-year survival, and sustained hemodynamic performance without valve reinterventions.
Answers are grounded in this paper and cite their sources.
Supports off-label Myval THV feasibility in non-aortic positions; leaves open need for randomized trials to guide practice.
Introduction and objectives: Transcatheter implantation of balloon-expandable valves in non-aortic positions represents a growing off-label strategy for valve-in-valve and valve-in-ring procedures in high-risk patients. We assessed 4-year clinical outcomes and echocardiographic performance of the transcatheter heart valve Myval THV implanted in the mitral, tricuspid, and pulmonary positions. Methods: This retrospective multicenter study included a total of 50 patients (mitral n = 33; tricuspid n = 13; pulmonary n = 4) treated across 11 centers, with clinical follow-up extending to 4 years and echocardiographic assessment of surviving patients. Results: Technical successs was achieved in 96.9% of mitral cases (1 procedural death) and in 100% of tricuspid and pulmonary cases. At 1 year, death had occurred in 2/33 (6.1%) mitral patients and in none of the tricuspid or pulmonary patients. At 4 years, death had occurred in 4/33 (12.1%) mitral, 2/13 (15.3%) tricuspid, and 0/4 pulmonary patients; stroke occurred in 0/33, 1/13 (7.6%), and 0/4 patients, respectively. Mean transvalvular gradients at 4 years were 8.5 ± 3.3 mmHg (mitral), 3.8 ± 1.6 mmHg (tricuspid), and 12.7 ± 9.9 mmHg (pulmonary). No moderate or greater bioprosthetic regurgitation was observed at 4-year echocardiographic assessment, and no valve reinterventions were recorded during follow-up. Conclusions: In this multicenter cohort, off-label use of the Myval THV in non-aortic positions demonstrated adequate midterm clinical outcomes and sustained echocardiographic performance up to 4 years. These preliminary findings support the feasibility of this transcatheter approach in selected patients but require further prospective validation.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2026) conducted an observational in Mitral valve disease requiring valve-in-valve, valve-in-ring, or valve-in-mitral annular calcification (ViMAC) intervention (n=33). Myval transcatheter heart valve was evaluated on 4-year all-cause death and bioprosthetic valve failure. Myval device implantation in the mitral position achieved 100% technical success in valve-in-valve and valve-in-ring subgroups with 0% structural valve deterioration at 4 years.
Synapse has enriched 10 related papers. Consider them for comparative context: